Welcome to our dedicated page for Scinai Immunotherapeutics Ltd. SEC filings (Ticker: SCNI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) files its regulatory reports as a foreign private issuer with the U.S. Securities and Exchange Commission, primarily through annual reports on Form 20‑F and current reports on Form 6‑K. This page provides access to those SEC filings, along with AI-assisted tools that help explain their contents in clear language.
In its 20‑F annual report, Scinai presents audited financial statements, a description of its dual business model in I&I biologics and CDMO services, risk factors, and details on capital structure and governance. The company’s 6‑K filings furnish interim information such as quarterly and half‑year financial results, business updates on Scinai Bioservices and the I&I pipeline, grant awards, and material agreements, including Standby Equity Purchase Agreements with Yorkville Advisors.
Recent 6‑Ks also describe grant applications and decisions related to programs like PC111, a human anti‑Fas Ligand monoclonal antibody in development via an option to acquire Pincell Srl, and governance matters such as changes in board composition and independent registered public accounting firms as part of cost-cutting measures. Other 6‑Ks incorporate press releases on Israel Innovation Authority funding for an advanced fill‑and‑finish system and business updates for the first half of 2025.
On Stock Titan, investors can review these filings in chronological order and use AI-powered summaries to quickly understand key points in lengthy documents. The platform highlights important elements in Scinai’s filings, such as financing arrangements, grant-related disclosures, and updates on its I&I and CDMO operations, helping readers navigate complex regulatory language without replacing the full text of the original SEC documents.
Scinai Immunotherapeutics Ltd. entered a new Standby Equity Purchase Agreement with YA II PN, Ltd. (Yorkville), giving Scinai the right, but not the obligation, to sell up to $15.0 million of its American Depositary Shares over 36 months. The ADSs, each representing 4,000 ordinary shares, will be priced at 97% of the lowest of three daily VWAPs during the three trading days starting on the date Scinai delivers an Advance Notice, and Scinai may set a minimum price per ADS in each Advance. Yorkville’s beneficial ownership is capped at 9.99% of the company’s voting power or ordinary shares. Scinai will pay a $108,000 commitment fee, half via issuance of 35,461 ADSs and half in cash, and the prior March 3, 2025 standby equity agreement with Yorkville will terminate once the new related registration statement is declared effective.
Scinai Immunotherapeutics Ltd. submitted a Form 6-K providing a business update for the first half of 2025. The filing includes a press release, condensed interim unaudited financial statements, and an operating and financial review and prospects, each as of June 30, 2025.
The company also states that this Form 6-K, including these exhibits, is incorporated by reference into its existing registration statements on Form S-8 and Form F-3. This links the new interim information directly into Scinai’s previously filed securities registration documents.